{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.3","value":"5.899"},{"groupId":"OG001","spread":"130.9","value":"4.048"}]}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.9","value":"12.551"},{"groupId":"OG001","spread":"133.1","value":"7.846"}]}],"title":"Cycle 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of belantamab mafodotin Total Antibody. As first dose of belantamab mafodotin was administered on Day 1, cycle length correlates to Day 1 plus 21 days i.e., Day 22 in timeframe.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and end stage renal disease (ESRD) (not on hemodialysis) received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.","id":"OG000","title":"Part 2: Belantamab Mafodotin 2.5 mg/kg End Stage Renal Disease (Not on Dialysis)"},{"description":"Participants with RRMM who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation) and ESRD (on hemodialysis) received IV infusion of 2.5 mg/kg belantamab mafodotin for 30 minutes on Day 1 of every 21-day Cycle until disease progression, withdrawal of consent, withdrawal due to AE, lost to follow-up, death, whichever occurs first.","id":"OG001","title":"Part 2: Belantamab Mafodotin 2.5 mg/kg ESRD (On Dialysis)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Evaluable population. 'Cycle 1' and 'Cycle 3' include the full first and third cycles, along with the Day 1 of Cycle 2 (C2D1) and Cycle 4 (C4D1) Predose periods, respectively. Only those participants who were measured and analyzed (i.e., contributed to data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.","reportingStatus":"POSTED","timeFrame":"Pre-dose, end of infusion (EOI), start of infusion (SOI)+2hour (h), SOI+4h, SOI+8h and SOI+24h on Cycle(C) 1 Day(D) 1 and C3D1; Anytime on C1 D4, D8, D15, D22; Anytime on C3 D4, D8, D15, D22; Pre-dose on C2D1 and C4D1.","title":"Part 2: Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) Following Administration of Belantamab Mafodotin (Total Antibody)","type":"PRIMARY","unitOfMeasure":"ug/mL"}